Weight loss does not decrease risk of breast cancer-related arm lymphedema.
breast cancer
breast cancer-related lymphedema
lymphedema
weight change
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
01 11 2021
01 11 2021
Historique:
revised:
06
06
2021
received:
10
06
2020
accepted:
28
06
2021
pubmed:
28
7
2021
medline:
11
3
2022
entrez:
27
7
2021
Statut:
ppublish
Résumé
The goal of this study was to determine the relationship between postoperative weight change and breast cancer-related lymphedema (BCRL). In this cohort study, 1161 women underwent unilateral breast surgery for breast cancer from 2005 to 2020 and were prospectively screened for BCRL. Arm volume measurements were obtained via an optoelectronic perometer preoperatively, postoperatively, and in the follow-up setting every 6 to 12 months. Mean follow-up from preoperative baseline was 49.1 months. The main outcome was BCRL, defined as a relative volume change of the ipsilateral arm of ≥10% at least 3 months after surgery. A total of 92 patients (7.9%) developed BCRL. Net weight loss versus net weight gain from baseline to last follow-up was not protective against developing BCRL (hazard ratio, 1.38; 95% confidence interval, 0.89-2.13; P = .152). Although weight loss may be recommended as part of an individualized lifestyle management program for overall health, weight loss alone may not decrease the risk of developing BCRL.
Sections du résumé
BACKGROUND
The goal of this study was to determine the relationship between postoperative weight change and breast cancer-related lymphedema (BCRL).
METHODS
In this cohort study, 1161 women underwent unilateral breast surgery for breast cancer from 2005 to 2020 and were prospectively screened for BCRL. Arm volume measurements were obtained via an optoelectronic perometer preoperatively, postoperatively, and in the follow-up setting every 6 to 12 months. Mean follow-up from preoperative baseline was 49.1 months. The main outcome was BCRL, defined as a relative volume change of the ipsilateral arm of ≥10% at least 3 months after surgery.
RESULTS
A total of 92 patients (7.9%) developed BCRL. Net weight loss versus net weight gain from baseline to last follow-up was not protective against developing BCRL (hazard ratio, 1.38; 95% confidence interval, 0.89-2.13; P = .152).
CONCLUSIONS
Although weight loss may be recommended as part of an individualized lifestyle management program for overall health, weight loss alone may not decrease the risk of developing BCRL.
Identifiants
pubmed: 34314022
doi: 10.1002/cncr.33819
pmc: PMC8516692
mid: NIHMS1723331
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3939-3945Subventions
Organisme : NCI NIH HHS
ID : R01 CA139118
Pays : United States
Organisme : Center for Strategic Scientific Initiatives, National Cancer Institute
ID : P50CA08393
Informations de copyright
© 2021 American Cancer Society.
Références
Lymphology. 1997 Jun;30(2):77-97
pubmed: 9215977
Lancet Oncol. 2013 May;14(6):500-15
pubmed: 23540561
BMC Cancer. 2017 Apr 12;17(1):259
pubmed: 28403873
Ann Transl Med. 2019 Apr;7(8):172
pubmed: 31168453
Gland Surg. 2018 Aug;7(4):379-403
pubmed: 30175055
Contemp Clin Trials. 2017 Oct;61:63-72
pubmed: 28739540
Cancer Causes Control. 2008 Dec;19(10):1319-28
pubmed: 18752034
Phys Ther. 2016 Dec;96(12):1965-1981
pubmed: 27340195
J Clin Oncol. 2016 Mar 1;34(7):691-8
pubmed: 26644530
World J Clin Oncol. 2014 Aug 10;5(3):241-7
pubmed: 25114841
Cancer Epidemiol Biomarkers Prev. 2010 Nov;19(11):2734-46
pubmed: 20978176
Breast Cancer Res Treat. 1992;22(2):129-32
pubmed: 1391977
J Pers Med. 2015 Sep 03;5(3):326-40
pubmed: 26404383
Int J Radiat Oncol Biol Phys. 2014 Mar 1;88(3):565-71
pubmed: 24411624
J Clin Oncol. 2005 Feb 1;23(4):774-82
pubmed: 15681521
J Pers Med. 2015 May 20;5(2):153-64
pubmed: 26011383
Ann Surg Oncol. 2009 Jul;16(7):1959-72
pubmed: 19365624
Ann Surg Oncol. 2012 Aug;19(8):2580-9
pubmed: 22395997
Breast Cancer Res Treat. 2010 Aug;122(3):823-33
pubmed: 20058068
Breast Cancer Res Treat. 2012 Sep;135(2):581-9
pubmed: 22869285
Cancer Pract. 2000 Sep-Oct;8(5):231-7
pubmed: 11898235
Int J Radiat Oncol Biol Phys. 2011 Apr 1;79(5):1436-43
pubmed: 20605339
J Clin Oncol. 2005 Mar 1;23(7):1370-8
pubmed: 15684320
Cancer Epidemiol Biomarkers Prev. 2007 Apr;16(4):775-82
pubmed: 17416770
Acta Oncol. 2007;46(8):1138-42
pubmed: 17851861
Ann Surg Oncol. 2010 Dec;17(12):3278-86
pubmed: 20574774
Int J Radiat Oncol Biol Phys. 2019 Jan 1;103(1):62-70
pubmed: 30165125
J Clin Oncol. 2008 Nov 10;26(32):5220-6
pubmed: 18838708
Cancer. 2007 May 15;109(10):1949-56
pubmed: 17393377
Breast Cancer Res Treat. 2007 Oct;105(2):177-86
pubmed: 17123151
J Clin Oncol. 2001 May 1;19(9):2367-9
pubmed: 11331314
Ulus Cerrahi Derg. 2015 Sep 01;31(3):124-7
pubmed: 26504414
Breast Cancer Res Treat. 2013 Nov;142(1):59-67
pubmed: 24122390
Cancer. 2007 Oct 15;110(8):1868-74
pubmed: 17823909
Lymphat Res Biol. 2011 Mar;9(1):13-8
pubmed: 21417763
Breast. 2016 Aug;28:29-36
pubmed: 27183497
Cancer. 2001 Sep 15;92(6):1368-77
pubmed: 11745212
Breast Cancer Res Treat. 2011 Dec;130(3):981-91
pubmed: 21761159